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Abstract
Background: Recent progress in molecular analysis has advanced the understanding of medulloblastoma (MB) and
is anticipated to facilitate management of the disease. MB is composed of 4 molecular subgroups: WNT, SHH,
Group 3, and Group 4. Macrophages play a crucial role in the tumor microenvironment; however, the functional
role of their activated phenotype (M1/M2) remains controversial. Herein, we investigate the correlation between
tumor-associated macrophage (TAM) recruitment within the MB subgroups and prognosis.
Methods: Molecular subgrouping was performed by a nanoString-based RNA assay on retrieved snap-frozen tissue
samples. Immunohistochemistry (IHC) and immunofluorescence (IF) assays were performed on subgroup identified
samples, and the number of polarized macrophages was quantified from IHC. Survival analyses were conducted on
collected clinical data and quantified macrophage data.
Results: TAM (M1/M2) recruitment in SHH MB was significantly higher compared to that in other subgroups. A
Kaplan-Meier survival curve and multivariate Cox regression demonstrated that high M1 expressers showed worse
overall survival (OS) and progression-free survival (PFS) than low M1 expressers in SHH MB, with relative risk (RR)
values of 11.918 and 6.022, respectively.
Conclusion: M1 rather than M2 correlates more strongly with worse outcome in SHH medulloblastoma.
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Background
Medulloblastoma (MB) is the most common pediatric
brain malignancy that frequently arises below 10 years of
age [1, 2]. Approximately 20–30% of patients remain
incurable, and high dose radiation and chemotherapy
frequently lead to significant long-term sequelae [3].
Progress in molecular diagnostics has revealed that MB
is classified into 4 subgroups: WNT, SHH, Group 3 (G3)
and Group 4 (G4) [1, 2, 4]. The prognosis of each
subgroup ranges from being excellent in WNT MB to
intermediate in SHH and G4, to poor in G3 MB [1, 4].
As subgroup-specific prognostication and personalized
medicine are in demand, clinically applicable
subgrouping has become essential [3, 5–7]. Practical
molecular subgrouping has been developed by multiple
researchers via screening subgroup-specific signature
genes using various tools, such as nanoString nCounter
[3, 4, 6].
The significance of lymphocytes and tumor-associated
macrophages (TAMs) in the tumor microenvironment
has been perpetually examined for more than a decade;
however, their comprehensive role is rather elusive [8–12].
TAMs release growth factors, cytokines, and inflammatory
mediators into the environment and are classified accord-
ing to their functional phenotype [13–16]. The current
paradigm of macrophage polarization is undergoing
reassessment. It has been commonly accepted that classic-
ally activated M1 macrophages suppress tumor growth
and progression by production of reactive oxygen species
(e.g., nitric oxide), whereas alternatively activated M2
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macrophages promote tumor growth and progression by
releasing growth factors (e.g., epidermal growth factor,
fibroblast growth factor 1, vascular endothelial growth fac-
tor A) [9, 13–16]. The literature has often described con-
flicting roles of TAMs in various cancers due to the
complexity of the tumor microenvironment and diverse
contributing factors, such as immune responses, tumor
stages, and types of tumors [11, 13, 17–20].
Despite the molecular insights provided by MB sub-
groups, relatively little is known about the role of tumor
microenvironment with respect to MB and its subgroups
[8]. A previous report on the characterization of immu-
nophenotype in pediatric brain tumors suggests that MB
is less infiltrated with T lymphocytes and displays an
immunosuppressive M2 phenotype compared to other
pediatric brain tumors [8]. A recent study demonstrated
that TAM recruitment is subgroup-specific in MB, sug-
gesting that the expression of TAM-associated genes
was significantly higher in the SHH subgroup [3]. This
finding indicates that SHH MB has a distinct tumor
microenvironment, which may have important patho-
physiological and therapeutic implications. However, the
roles of TAMs and their activation phenotypes are
inconclusive because the previous study did not present
the prognostic connotations of TAMs in SHH MB [3].
In the present study, we investigate the correlation
between TAM recruitment in SHH MB with prognosis.
We identified that M1 macrophage recruitment rather
than total TAM recruitment correlates more strongly
with a reduced overall survival outcome within the SHH
subgroup. Considering the commonly accepted role of
macrophage polarization in various human cancers (M1
tumor-suppressing and M2 tumor-promoting roles), the
negative prognostic implication of M1 macrophages in
SHH MB is intriguing and requires further investigation.
Methods
Patients and samples
The Institutional Review Board (IRB) of the Seoul National
University Hospital (SNUH) approved the study protocol
(IRB approval No. 1610–027-797). To identify SHH MB,
48 snap-frozen MB tissues were retrieved from the Brain
Bank of the Department of Neurosurgery, Seoul National
University Hospital. Tissue samples were collected from
141 MB patients who underwent surgery at Seoul National
University Children’s Hospital (SNUCH) from 1999 to
2015. The molecular subgroups of the samples were par-
tially verified via immunohistochemistry (IHC) using repre-
sentative markers [4]. To solidify the molecular subgroup,
a nanoString-based RNA assay was performed on these
samples. Previously, we provided MB tissues to Dr. M. Tay-
lor from the Hospital for Sick Children (Toronto, Canada)
for analysis, and the molecular subgroups were provided
for these cases through nanoString [10].
We collected 32 SHH MBs from two sources: cases
newly tested for subgrouping (n = 16) and cases with sub-
group information from Toronto (n = 16). Among the 32
known SHH MB patients, 25 patients had available
formalin-fixed paraffin-embedded (FFPE) tissues. Two
FFPE tissue samples were removed from selection due to
small tissue size or the inability to undergo a complete ex-
periment; 23 SHH MB samples were finally recruited from
our institution. An additional 7 SHH MB FFPE tissue
samples were received from Yonsei University. In total, 30
SHH MB were analyzed in the present study. Subgroups
other than SHH were randomly selected with respect to
FFPE tissue availability as control groups to validate the
correlation between TAM infiltration and the prognosis
of the subgroups (WNT= 3, Group 3 = 2, Group 4 = 17).
Subgrouping
Molecular subgroups were identified through gene pro-
filing using nanoString nCounter [6]. Total RNA was ex-
tracted from snap-frozen patient tissue samples (n = 48)
using the miRNeasy kit according to the manufacturer’s
protocol (Life Technologies, Carlsbad, CA, USA). Proce-
dures related to hybridization, detection and scanning
were performed as recommended by nanoString Tech-
nologies (Seattle, WA, USA). The collected data were
normalized in R, and an algorithm for class prediction
analysis was provided by Dr. M. Taylor (Toronto,
Canada) [6]. The subgroup of additionally received FFPE
tissue samples from Yonsei University, which were iden-
tified via immunohistochemistry (IHC), was provided by
Dr. SH Kim (Seoul, Korea). For the SHH subgroup, IHC
generally yields stable and concordant results with
nanoString.
Immunohistochemistry
Macrophage recruitment was investigated using immu-
nohistochemistry (IHC) on FFPE tissue samples (n = 45).
Human tonsil tissue was used as a positive control
(Additional file 1: Figure S1).The recruitment of acti-
vated macrophages was identified using the following
antibodies: CD68 for total macrophages, CD86 for M1-
activation, and CD163 for M2-activation (Additional file 2:
Table S1). Five hot spots were randomly selected in each
paraffin section, and positive cells among the 300 counter-
stained cells were counted using the ImageJ Cell Counter
plugin [21]. The mean value of the five hot-spots count
was used in the following statistical analyses. Researchers
engaged in the present experiment were blinded from all
clinical data, including subgroup, through data collection.
Immunofluorescence
To confirm the independent localization of M1 and M2
macrophages, an immunofluorescence (IF) assay was
performed on FFPE tissue samples. The retrieved blocks
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were sectioned at 4 μm using a microtome and trans-
ferred to silane-coated slides by the SNUH pathology
lab. The slides were deparaffinized in xylene and rehy-
drated through a graded ethanol series. To retrieve anti-
gen, the slides were microwaved in 10 mM sodium
citrate buffer (pH 6.0) for 3 min, with a 15 s cooling
interval after 2 min. The slides were washed three times
in phosphate-buffered saline (PBS) with 0.1% bovine
serum albumin (BSA) for 5 min each and then perme-
abilized (1× PBS/ Timerasol: 95 mg/L, saponin: 0.6 g/L,
normal goat serum: 1%) for 15 min. The slides were sub-
sequently blocked in blocking solution (1 × PBS/ Time-
rasol: 95 mg/L, saponin: 0.35 g/L, normal goat serum: 3.
5%) for 30 min at room temperature [22]. The primary
antibody was prepared in a modified blocking solution
(1 × PBS/ Timerasol: 95 mg/L, saponin: 0.1 g/L, normal
goat serum: 1%), with adequate dilution and incubated
overnight at 4 °C. The secondary antibody was similarly
diluted accordingly and applied for 1 h at room
temperature.
Clinical data
Clinical data, including sex, age at diagnosis, pathology,
degree of surgical resection, presence of leptomeningeal
seeding at presentation, applied treatment modalities, pro-
gression, and survival, were collected independently of the
researchers conducting the experiments. Progression-free
survival (PFS) refers to the time interval from the day of
initial surgery to the date when tumor progression was
radiologically identified or the date of the last follow-up
[10]. Overall survival (OS) refers to the time interval from
the day of initial surgery to the date of patient death or
the date of the last follow-up [10].
All 32 patients with SHH MB received chemotherapy. The
chemotherapy regimens changed from 1999 to 2015. Prior
to 2006, the Children’s Cancer Group (CCG) 9921 regimen
(3 patients) or the 8 in 1 (6 patients) regimen were applied,
and from 2006, the KSPNO (Korean Society for Pediatric
Neuro-Oncology) protocols for infant or child MB were
applied (14 patients). Eleven patients were aged < 3 yrs. at
diagnosis, and radiation therapy (RT) was delayed for these
patients. Overall, 20 patients received RT. The RT doses
were adapted to the risk status of each patient: the standard
risk group: craniospinal axis 19.8–23.4 Gy, tumor bed boost
up to 54 Gy; the high risk group: craniospinal axis 28.8–
36 Gy, tumor bed boost up to 54 Gy. The three patients for
whom RT was delayed did not receive RT. One patient was
lost to follow-up prior to initiating RT, while another patient
died at 11 months with rapid disease progression, and
another patient was cured with chemotherapy alone.
Statistical analysis
Subgroup prediction analysis was conducted in R. IBM
SPSS Statistics version 23 was used to perform common
statistical analyses, including χ2, bivariate Pearson’s
correlation, Cox regression analysis, survival analysis,
and the log-rank test as previously described [10].
Appropriate indications are provided in the text and
supplementary data.
Results
Identification of molecular subgroupsusing nanoString
nCounter
To identify SHH MB, we performed gene profiling on 22
subgroup-specific signature genes on selected samples
(n = 48) using nanoString nCounter [6]. We identified 5
WNT, 16 SHH, 5 Group3, and 26 Group4 MBs through
class prediction analysis (Additional file 1: Figure S2); 7
of the 16 patients identified as SHH subgroup had ad-
equate FFPE tissue samples available. Additionally, 16
SHH samples previously identified by the same method
in Toronto were incorporated in the present study,
yielding a total number of 23 SHH samples. Moreover,
22 randomly selected non-SHH subgroup samples were
analyzed as control groups for the reliability and validity
of IHC/IF techniques and counting. The subgroup of the
validation cohort was pre-identified by immunohisto-
chemistry only.
Activated macrophage recruitment in the
medulloblastoma subgroups
First, we investigated the unique recruitment pattern of
tumor-associated macrophages (TAM) in the different MB
subgroups. Immunohistochemistry (IHC) analysis was con-
ducted to identify macrophage recruitment (Fig. 1a), and
the recruited proportion of CD68-, CD86-, and CD163-
positive macrophages were quantified in each subgroup
(Fig. 2a & b). The comparison was largely SHH to G4 since
the numbers of other subgroups was limited. Notably,
CD163-positive M2 macrophages were significantly higher
in the SHH subgroup (n = 23) compared to that in another
subgroup (n = 22) (P < .001). M1 macrophage recruitment
was also significantly higher in the SHH subgroup than that
in non-SHH subgroups (P = .048). Through immunofluor-
escence (IF) analysis, we confirmed that M1 and M2 mac-
rophages, identified by CD86 and CD163, respectively,
were located in different areas and were independently dis-
tinguishable (Fig. 1b).
TAM recruitment and patient characteristics
The M2 macrophage proportion also correlated with
patients < 3 years of age (P = .015) and the lateral loca-
tion of the tumor (P = .008), which are known indicators
of the SHH subgroup (Fig. 2c). We verified that the
present quantification method and results were consist-
ent with the findings of a previous study that used a dif-
ferent quantification method [3].
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TAM recruitment and survival outcomes in MB
Statistical analysis was conducted on the collected data
to demonstrate the correlation between TAM in MB
and prognosis. We dichotomously defined patient
groups of high and low macrophage expressers based on
the median-value of the macrophage counts. OS and
PFS analyses on counted M1 and M2 activation markers
were performed using the Kaplan-Meier plot and log-
rank test (Additional file 1: Figure S3). MB patients with
high M1 counts showed a considerable trend with
shorter OS (P = .064). However, patients with high M2
counts showed shorter PFS (P = .037), which did not
affect the OS of these patients. Considering that
approximately half of all included cases were of the SHH
subgroup and TAM is overrepresented only in this sub-
group, the prognostic implications may be more clear in
the SHH subgroup.
TAM recruitment and survival outcomes in SHH MB
We investigated whether SHH-specific macrophage re-
cruitment showed a correlation with the survival outcomes
in SHH MB (Fig. 3). High M1 expressers had shorter OS
(P = .013) and a trend with shorter PFS (P = .065). Prognos-
tic factors those are known to affect the outcomes, such as
sex, age, and leptomeningeal seeding, were incorporated in
multivariate Cox regression analysis (Tables 1 & 2).
ba
Fig. 1 TAM recruitment across MB subgroups. (a) Representative CD68, CD86, and CD163 IHC images in WNT (n = 3), SHH (n = 23), Group 3 (n = 2) and
Group 4 (n = 17) subgroups. Scale bar, 50 μm (b) Representative CD86 and CD163 IF images in each subgroup. Scale bar, 50 μm
a c
b
Fig. 2 Proportion of TAM recruitment in MB. (a) Comparison of macrophage recruitment between the 4 subgroups. The one-way ANOVA results are
presented; however, due to the small number of WNT and Group 3 subgroup samples, statistical significance is neglected. (b) Comparison between
SHH and non-SHH subgroups; CD68 (P = .035), CD86 (P = .042), and CD163 (P < .0001) were significantly higher in the SHH subgroup than those in the
non-SHH subgroups. (c) CD163-positive macrophages were significantly higher in patients younger than 3 years-of-age (P = .015) as well as the lateral
location of the tumor (P = .008)
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Interestingly, high M1 macrophages were significantly cor-
related with shorter OS (P = .030, RR = 11.918, 95% CI = 1.
265–112.282) and PFS (P = .027, RR = 6.022, 95% CI = 1.
232–29.433) in the SHH subgroup (Fig. 4). M2 macrophage
recruitment did not show an obvious correlation with the
outcome of SHH subgroup patients (Fig. 3b, Table 2).
TAM recruitment and other prognostic factors in SHH MB
With respect to the TAM infiltration within MB, other
prognostic factors were investigated to identify potential
correlations (Table 3). A multivariate analysis using
binary logistic regression revealed that age, lateral tumor
location, and large residual tumor (> 1.5cm2) were not
significantly related to the M1 and M2 macrophage
recruitment patterns in SHH MB (Additional file 2:
Table. S2).
TAM and survival outcome correlation in other cohort
To further confirm the correlation between TAM
recruitment and survival outcome, 7 additional SHH
MB from other cohorts were separately investigated
(Additional file 1: Figure S4). Due to the short follow-up
(FU) period and small population, the correlation
between TAM recruitment and survival outcome was
not significant, but the survival graphs showed a consid-
erable trend with the current study cohort.
Discussion
We demonstrate an unconventional correlation between
subgroup-specific recruitment of TAM in SHH MB and
prognosis. We confirmed subgroup-specific augmenta-
tion of M1 and M2 macrophages in SHH MB and com-
pared this result with relevant prognostic factors.
Survival analyses and Cox-regression analysis showed
that M1 rather than M2 infiltration correlates better
with worse OS and PFS in SHH MB, with relative risk
values of 11.918 and 6.022, respectively.
The SHH MB subgroup, as suggested by its name, is
thought to be driven by alterations in the Sonic-
hedgehog signaling pathway [4]. The SHH pathway plays
a crucial role in cerebellar development, inducing the
proliferation of neuronal precursors [1, 4]. Individuals
with germline or somatic mutations in the SHH path-
way, such as PTCH, SMO, SUFU, GLI1, and GLI2, are
predisposed to MB [1, 4]. Moreover, SHH MB has an
intermediate prognosis among the 4 subgroups but,
interestingly, is saturated with the highest number of
TAMs, as demonstrated in the present and the previous
one [1, 3]. A dichotomous age distribution (< 4 years
and > 16 years) is another hallmark of SHH subgroup;
the present study showed that the age distribution
within SHH MB did not significantly correlate with acti-
vated macrophage recruitment [1].
ba
Fig. 3 TAM recruitment and prognostic outcomes in SHH MB. (a) PFS and OS analyses using Kaplan-Meier plots and the log-rank test based on
the CD86-positive macrophage counts. High M1 recruitment is correlated with shorter PFS (P = .065) and OS (P = .013). (b) PFS and OS analyses
based on the CD163-positive macrophage counts. M2 recruitment did not show an obvious correlation with the prognostic outcome
Table 1 Relative risks for shorter PFS in SHH MB estimated with a Cox proportional hazards model
Clinical Factor Univariate analysis Multivariate analysis
P value RR 95% CI P value RR 95% CI
M1 Count .085 3.331 .848–13.091 .027 6.022 1.232–29.433
M2 Count .399 1.727 .485–6.151 .246 2.361 .553–10.076
Age .700 1.029 .890–1.190 .687 1.031 .890–1.194
Sex (Male)a .098 .316 .081–1.237 .117 .256 .046–1.408
Leptomeningeal
Seeding
.319 1.994 .514–7.736 .521 1.721 .328–9.037
RR Relative risk, CI Confidence interval
aSex was included in the multivariate analysis model as a basic variable
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The recognition of microenvironment in tumor biology
has escalated over the past few decades, and this emphasis
has led researchers to characterize contributing factors,
including immunophenotypes, in various cancers [8].
However, these studies are often limited to phenotypic
characterization and lacked prognostic connotation. A
previous study investigated TAM recruitment in MB and
proposed subgroup-specific recruitment in SHH MB [3].
We sought to verify this phenomenal recruitment in MB
by a different method. Indeed, we found corroborating re-
sults showing augmented TAM recruitment in SHH MB
and confirmed its unique microenvironment. Aside from
M2 macrophages, we further characterized M1 macro-
phages in SHH MB and investigated the prognostic con-
notation of their recruitment.
In the present study, high M1 macrophages correlated
with poor prognosis in SHH MB patients. This result ap-
parently contradicts the common view of tumoricidal
M1 macrophages. In many cancer types, M1 macro-
phage infiltration is associated with better prognosis
[23–25]. However, recent studies suggest that the dichot-
omous M1/M2 classification is oversimplified, and the
role of TAM in tumors is still controversial [14, 26]. We
cannot provide a conclusive role for M1 macrophages in
SHH MB because the causality of the worse prognosis
associated with M1 macrophages has not been investi-
gated. However, few plausible hypotheses can be made
from the present results: 1) high M1 macrophage re-
cruitment assists growth and progression of SHH MB
contrary to its role in other cancers, 2) M1 macrophages
are highly recruited to enhance the tumoricidal effect in
aggressive group of SHH MB, but this mechanism alone
was insufficient to fight the particular malignancy, or 3)
high M1 recruitment is an epiphenomenon, and these
cells are simply recruited by other SHH MB initiators
and do not directly affect prognosis. Interestingly, the
literature suggests multiple perspectives. The loss of
nitric oxide synthase2 (NOS2) in the Ptch1+/-SHH MB
mouse model was reported to promote development of
medulloblastoma [27]. NOS2 is a key enzyme that
produces nitric oxide in M1 macrophages in response to
pathogens [26]. This suggests good prognostic role of
M1 macrophages, which supports the second
hypothesis. However, direct production of interferon-γ, a
known stimulatory cytokine of M1 macrophages, in the
developing brain was reported to activate the SHH
pathway and cerebellar dysplasia. [28]. This activation
may suggest that M1 macrophages are coincidentally
recruited in response to the abnormal source of IFN-γ
in the developing brain, not in recognition of MB or to
Table 2 Relative risks for shorter OS in SHH MB estimated with a Cox proportional hazards model
Clinical Factor Univariate analysis Multivariate analysis
P value RR 95% CI P value RR 95% CI
M1 Count .038 9.558 1.128–81.002 .030 11.918 1.265–112.282
M2 Count .940 1.060 .234–4.801 .601 .620 .104–3.710
Age .111 1.146 .969–1.354 .180 1.118 .950–1.316
Sex (Male)a .044 .117 .014–0.948 .080 .110 .009–1.298
Leptomeningeal Seeding .064 4.693 .917–24.026 .422 2.097 .344–12.786
RR, Relative risk; CI, Confidence interval
aSex was included in the multivariate analysis model as a basic variable














Number 12 11 12 11
Mean 6.4 ± .6 2.1 ± .3 11.2 ± .4 4.6 ± .7
Age 5.0 ± 1.1 4.6 ± 1.5 5.7 ± 1.4 4.0 ± 1.2
M:F 7:5 5:6 7:5 5:6
Lateral tumor location 7 (30%) 7 (30%) 8 (35%) 6 (26%)
Gross total resection 10 (43%) 6 (26%) 9 (39%) 7 (30%)
Large residual tumor (> 1.5cm2) 1 (4%) 3 (13%) 2 (9%) 2 (9%)
Leptomeningeal Seeding 3 (13%) 2 (9%) 3 (13%) 2 (9%)
aHigh expressers indicates patients with greater than or equal to median count.
bLow expressers indicates patients with lower than median count
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destroy it. Such conflicting perspectives may also suggest
a context-dependent role for TAM.
The small number of patients is a major limitation of
the present study. The heterogeneity of the treatment
administered to the patients may also confound the re-
sults, although all patients followed modernized treat-
ment protocols in terms of risk stratification,
chemotherapy regimen, and RT doses. Further validation
in a comparable MB cohort is required to consolidate
the role of TAM in SHH MB.
Conclusion
High M1 macrophage recruitment correlated with a worse
prognostic outcome in SHH MB. The present results are
unconventional, yet intriguing, as the commonly accepted
role of M1 macrophages should demonstrate the opposite
effect. However, additional follow-up studies are required;
the present study is limited because of its small sample size
and strong dependence on the IHC results. Further in vitro
and in vivo studies should be performed to determine the
mechanism and causality of the worse prognostic outcome
associated with M1 macrophages in SHH MB.
Additional files
Additional file 1: Figure S1. Macrophage recruitment in human tonsil
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Correlation between TAM and other prognostic factors estimated with a
logistic regression in SHH MB. (DOCX 17 kb)
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